Molbio Diagnostics Limited IPO

Molbio is an innovative point-of-care diagnostics enterprise focused on expanding access to accurate, rapid, and cost-effective healthcare technologies for the diagnosis of infectious and non-communicable diseases. Its portable, battery-operated “Truenat” platform enables molecular diagnosis using disease-specific test kits with results available within an hour. As of Mar 31, 25, the Truenat platform supports screening and diagnosis for over 30 diseases, including tuberculosis, COVID-19, Hepatitis B and C, human immunodeficiency virus, and human papillomavirus. In addition to molecular diagnostics, the Company offers devices for radiology, digital pathology, and breast health screening. Its products are supplied globally to public health programs, diagnostic laboratories, and private and public hospitals.